Lineage Cell Therapeutics (LCTX)
(Delayed Data from AMEX)
$1.05 USD
+0.02 (1.94%)
Updated May 24, 2024 04:00 PM ET
After-Market: $1.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LCTX 1.05 +0.02(1.94%)
Will LCTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LCTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LCTX
Lineage (LCTX) Up 10% on Upbeat Data From Eye Disease Study
Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates
LCTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates
U.S. Physical Therapy (USPH) Beats Q2 Earnings and Revenue Estimates
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Other News for LCTX
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
Buy Rating on Lineage Therapeutics Backed by Roche Collaboration and Solid Financials
Analysts Are Bullish on These Healthcare Stocks: Oncolytics Biotech (ONCY), Lineage Therap (LCTX)
Analysts’ Top Healthcare Picks: Caribou Biosciences (CRBU), Lineage Therap (LCTX)
Lineage Cell Therapeutics Q1 2024 Earnings: Aligns with EPS Projections Amidst Revenue Declines